利用转基因玉米研制新型结核口服疫苗.构建植物双元表达质粒pCAMBIA1300GHLE,并转化农杆菌LBA0.以本实验室构建的pEGHLE为模板经聚合酶链反应(PCR)扩增出Hsp65-Esat6基因,连接到含有玉米特异性启动子globulin-1的pCR2.1载体上;将globulin1-HLE联合片断切下连到含有抗除草剂基因bar的pCAMBIA1300载体中;电击法将重组质粒转化到农杆菌LBA0中.成功构建了pC1300GHLE质粒,酶切鉴定得到3.3 kb和8.6Kb2条带,测序分析表明克隆的H8p65和Esat6序列与NCBI上公布序列一致;成功转化到农杆菌中,酶切从农杆菌中所提的质粒,条带大小与预期结果相符合.成功构建和转化了pCl300GHLE表达载体,为成功研制利用转基因植物生产抗结核口服疫苗奠定了基础.
李君武
,
王珊珊
,
宋东
,
刘艳
,
黄清华
. 玉米特异启动子驱动下结核Hsp65与Esat-6融合基因表达载体的构建及鉴定[J]. 华北农学报, 2009
, 24(3)
: 28
-31
.
DOI: 10.7668/hbnxb.2009.03.006
To construct the plant expression plasmid containing Mycobacterium tuberculosis Hsp65 and Esat26 genes, and transform the recombined vector into Agrobacterium tumerfaciens LBA4404. The fusion DNA fragment of Hsp65 and Esat26 were amplied from pEGHLE by polymerase chain reaction(PCR)were cloned into the vector pCRG. The combine fragment of promoter globulin21 and the target gene HLE which get from doubled enzymes digestion of the recombined plasmid pCRGHLE was inserted into the plant expression vector pCAMBIA1300 which contain the gene bar for herbicide resistance. The recombinant plasmid was analyzed by restriction enzyme digestion and the inserted target genes in the pC1300GHLE were verified by nucleotide sequencing. Then transformed pC1300GHLE vector into Agrobacterium tumerfa2 ciens LBA4404 by electroporation. The binary expression plasmid,which could express HSP65 and ESAT26,was correctly constructed. The recombinant vector containing Mycobacterium tuberculosis Hsp65 and Esat26 genes is constructed suc2 cessfully and transformed into LBA4404,and lays a foundation for further study on its immunity effectiveness against MTB.
[1] Mustaesa S.Developmentofitew vaccines and diagnostic reagents against tuberculosis[J].Molecular Immunology,2002,39:113-119.
[2] Lowrie D B,Tasconr E,Bonatovl D,et al.Therapy of tubercu-losis in mice by DNA vaccination[J].Nature,1999,400:269-271.
[3] 师长宏,范雄林,柏银兰,等.结核分枝杆菌Ag85B-ESAT6融合蛋白在小鼠体内诱导的免疫应答及其保护力[J].第四军医大学学报,2004,25(18):1633-1636.
[4] 师长宏,安家泽,唐小凤,等.结核分枝杆菌MPT64-ESAT6融合蛋白在小鼠内诱导的免疫应答及其保护力[J].第四军医大学学报,2006,27(9):769-771.
[5] Paton D J,Valarcher J F,Bergnmnn I,et al.Selection of foot and mouth disease vaccine strains-a review[J].Rev Sci Tech,2005,24.
[6] Kaufmann S H E.Heat shock proteins and the immune re-sponse[J].Immunol Today,1990,11(1):129-136.
[7] Johansen P,Raynaud C,Yang M,et al.Anti-mycobacterial immunity induced by a singh injection of M.leprae HSP65-encoding plasmid DNA inbiodegradable microparticles[J].Inununol Lett,2003,90(2-3):81-85.
[8] Trajkovic V,Natarajan K,Sharma P.Immunomodulatory ac-tion of mycobacterial secretory proteins[J].Microbes Infect 2004,6(5):513-519.
[9] Lowrie D B,Tascon R E,Colston M J,et al.Towards a DNA vaccine against tuberculosis[J].Vaccine,1994,12:1537-1540.
[10] Ravn P,Demissie A,Eguale T,et al.Human T cell response to the ESAT-6 antigen from Mycobacterium tuberculosis[J].J Infect Dis,1999,179:637-645.
[11] Hongxun S,Vladimir M P,Corey M,et al.Regiona,I but not systemicrecroitment,expansion of dendritic cells by a pluron-ic-formulated Flt3-ligand plasmid with vaccine adjuvant ac-tivity[J].Vaccine,2003,21(26):3019-3020.
[12] 李林,佳飞.转基因植物口服疫苗的免疫机制研究进展[J].国外医学免疫学分册,2004,27(6):354-357.
[13] 郝浩永,尉亚辉.转基因番茄表达121服乙肝疫苗[J].食品科学,2007,28(6):201-204.
[14] 陈珍,陈文莉.转基因植物口服疫苗研究的新进展[J].细胞与分子免疫学杂志,2006,22(6):831-833.
